ArticleLiver cancer2024

Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study.

Heechul Nam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.